Skip to main content

Table 1 The 50 % inhibitory concentration (IC50) of cisplatin in A549 and A549/DDP cells 48 h after drug treatment

From: RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells

Cell Control siFANCF siFANCL siFANCF+ siFANCD2 siFANCD2+ siFANCD2+
siFANCL   siFANCF siFANCL
A549 4.97 ± 0.32 3.05 ± 0.24a 2.46 ± 0.21b 2.44 ± 0.27 b 2.48 ± 0.31 b 2.45 ± 0.18 b 2.40 ± 0.23 b
A549/DDP 34.15 ± 0.42 4.43 ± 0.28c 2.51 ± 0.33c, d 2.48 ± 0.25 c, d 2.54 ± 0.17 c, d 2.52 ± 0.22 c, d 2.47 ± 0.19 c, d
SK-MES-1 9.92 ± 0.35 3.47 ± 0.25c 2.68 ± 0.29c 2.45 ± 0.32c 2.58 ± 0.23c 2.50 ± 0.33c 2.46 ± 0.35c
  1. acompared with control, p = 0.009; bcompared with control, p = 0.001; ccompared with control, p < 0.001; dcompared with siFANCF, p < 0.001